Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), both competing one another are Biotechnology companies. We will compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Xenon Pharmaceuticals Inc.||10||0.00||N/A||-1.73||0.00|
|Conatus Pharmaceuticals Inc.||1||0.42||N/A||-0.57||0.00|
Demonstrates Xenon Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.
Table 2 shows us Xenon Pharmaceuticals Inc. and Conatus Pharmaceuticals Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Xenon Pharmaceuticals Inc.||0.00%||0%||0%|
|Conatus Pharmaceuticals Inc.||0.00%||-81%||-32.8%|
Risk & Volatility
Xenon Pharmaceuticals Inc. has a beta of 1.32 and its 32.00% more volatile than Standard & Poor’s 500. Conatus Pharmaceuticals Inc.’s 120.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 2.2 beta.
The Current Ratio and a Quick Ratio of Xenon Pharmaceuticals Inc. are 17.6 and 17.6. Competitively, Conatus Pharmaceuticals Inc. has 2.4 and 2.4 for Current and Quick Ratio. Xenon Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Conatus Pharmaceuticals Inc.
Insider and Institutional Ownership
Roughly 76.9% of Xenon Pharmaceuticals Inc. shares are held by institutional investors while 25.1% of Conatus Pharmaceuticals Inc. are owned by institutional investors. 0.7% are Xenon Pharmaceuticals Inc.’s share held by insiders. Competitively, insiders own roughly 3.34% of Conatus Pharmaceuticals Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Xenon Pharmaceuticals Inc.||-0.41%||-6.96%||10.83%||17.32%||4.57%||52.46%|
|Conatus Pharmaceuticals Inc.||-9.55%||17.93%||-61.64%||-86.16%||-91.73%||-81.6%|
For the past year Xenon Pharmaceuticals Inc. had bullish trend while Conatus Pharmaceuticals Inc. had bearish trend.
On 5 of the 7 factors Xenon Pharmaceuticals Inc. beats Conatus Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.